Gilead Stock: Buy The Distortion Before Q2 Clears It Up (NASDAQ:GILD)
· seekingalpha.com
Gilead Sciences HIV franchise is growing 8% with patent protection through 2036 and up to seven new launches by 2033. Read why GILD stock is a buy.
There is a specific kind of number that is making a perfectly healthy business look like it is in shambles, and Gilead Sciences ( GILD ) is about to be one of t...